Interview: Manni Kantipudi – CEO, GVK BIO, India
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
Address: 142 AB, Kandivli Co-operative
Industrial Estate Ltd.,
Kandivli (West),
Mumbai – 400 067. Maharashtra,India
Tel: +91 (022) 6647 4747
Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca’s APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). With operations in over 100 countries, exports account for over 52% of the company’s income.
Forbes, a leading US business magazine, selected Ipca in 2003 among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. Over 19,000 companies were considered by Forbes, and of the 18 companies from India that figured in this list, only four were from the ‘Indian Pharmaceutical Sector’. Ipca happens to be one of them. Subsequently, Ipca was selected by FORBES in this prestigious list for two consecutive years; 2004 and 2005.
From a modest income of Rs. 0.54 crores in 1975-76, the net income has soared to Rs. 753.30 crores in 2005-06 with exports accounting for Rs. 401.83 crores. The net profit for the year ending 31st March, 2006 stood at Rs. 63.98 crores. Formulations constitute 67 percent of the total income for 2005-06. Today, Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over.
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
Satish Kumar Singh (managing director) & Shashi Shekhar Kumar (vice president International Business) from M/s Cachet Pharmaceuticals Pvt. Ltd., discuss their success with special reference to marketing, distribution and operating…
A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar…
A nationwide renowned neonatologist and member of the High Level Expert Group on Universal Health Coverage, NITI Aayog’s medical expert, Dr. Vinod K. Paul introduces the work that the government…
Newly appointed commissioner of the Food & Drugs Administration (FDA) of the Indian state of Maharashtra, Dr. Pallavi Darade, shares her objectives to further consolidate the FDA’s positioning as a…
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen –…
Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how…
Janmejay Vyas, chairman of the Dishman Group, shares the story of his success in establishing a trustworthy relationship with the strictest drug regulator in the world, the US FDA. Mr…
See our Cookie Privacy Policy Here
